HLA-DRB1*04/*13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 1018-1025

  Lundström, Emeli ^a   Gustafsson, Johanna T ^a   Jönsen, Andreas ^b   Leonard, Dag ^c   Zickert, Agneta ^a   Elvin, Kerstin ^a   Sturfelt, Gunnar ^b   Nordmark, Gunnel ^c   Bengtsson, Anders A ^b   Sundin, Ulf ^a   Källberg, Henrik ^d   Sandling, Johanna K ^c   Syvänen, Ann Christine ^c   Klareskog, Lars ^a   Gunnarsson, Iva ^a   Rönnblom, Lars ^c   Padyukov, Leonid ^a   Svenungsson, Elisabet ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; HLA DRB1 ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; AUTOANTIBODY; HLA DRB1*04 ANTIGEN; HLA DRB1*13 ANTIGEN; HLA-DRB1*04 ANTIGEN; HLA-DRB1*13 ANTIGEN;

ADULT; ALLELE; ANTIBODY DETECTION; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HLA DRB1 GENE; HUMAN; IMMUNOPHENOTYPING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; AGED; ANTIPHOSPHOLIPID ANTIBODIES; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; GENETICS; GENOTYPE; HEART MUSCLE ISCHEMIA; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE;

ANTIPHOSPHOLIPID ANTIBODIES; AUTOANTIBODIES; CARDIOVASCULAR DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; BRAIN ISCHEMIA; COHORT STUDIES; FEMALE; GENOTYPE; HLA-DRB1 CHAINS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; VASCULAR DISEASES; VENOUS THROMBOEMBOLISM;

MLCS; MLOWN;

EID: 84877604619     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201760     Document Type: Article

References (51)

1. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort. Ann Rheum Dis 2009;68:238-41.
2. Calvo-Alen J, Toloza SM, Fernandez M, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005;52:2060-8. (Pubitemid 40994330)
3. Bjornadal L, Yin L, Granath F, et al. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004;31:713-19. (Pubitemid 38451257)
4. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550-7. (Pubitemid 44205016)
5. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7. (Pubitemid 32977500)
6. Gustafsson J, Gunnarsson I, Borjesson O, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus-a prospective cohort study. Arthritis Res Ther 2009;11:R186.
7. Toloza SM, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57. (Pubitemid 39643943)
8. Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity 2007;40:560-6. (Pubitemid 350302182)
9. Fernando MM, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet 2008;4:e1000024.
10. Graham RR, Ortmann W, Rodine P, et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur J Hum Genet 2007;15:823-30. (Pubitemid 47109040)
11. Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1228-33.
12. Harley JB, Alarcon-Riquelme ME, Criswell LA, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008;40:204-10. (Pubitemid 351171405)
13. Hom G, Graham RR, Modrek B, et al. Association of Systemic Lupus Erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900-9. (Pubitemid 351397089)
14. Ohlenschlaeger T, Garred P, Madsen HO, et al. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260-7. (Pubitemid 38916043)
15. Karassa FB, Bijl M, Davies KA, et al. Role of the Fcgamma receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003;48:1930-8. (Pubitemid 36828688)
16. Szalai AJ, Alarcon GS, Calvo-Alen J, et al. Systemic lupus erythematosus in a multiethnic US Cohort (LUMINA). XXX: association between C-reactive protein (CRP) gene polymorphisms and vascular events. Rheumatology 2005;44:864-8. (Pubitemid 41511179)
17. Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010;69:834-40.
18. Arnett FC, Thiagarajan P, Ahn C, et al. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 1999;42:268-74. (Pubitemid 29072843)
19. Bertolaccini ML, Atsumi T, Caliz AR, et al. Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 2000;43:683-8. (Pubitemid 30394961)
20. Galeazzi M, Sebastiani GD, Tincani A, et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000;9:47-55. (Pubitemid 30265118)
21. Sebastiani GD, Morozzi G, Bellisai F, et al. Anti-cofactor autoantibodies in systemic lupus erythematosus: prevalence, clinical and HLA class II associations. Immunoll Invest 2008;37:375-85. (Pubitemid 351892619)
22. Gustafsson J, Gunnarsson I, Pettersson S, et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012;14:R46.
23. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010;19:419-23.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
25. Stolt P, Bengtsson C, Nordmark B, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41. (Pubitemid 37026493)
26. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
27. Andersson T, Alfredsson L, Kallberg H, et al. Calculating measures of biological interaction. Eur J Epidemiol 2005;20:575-9. (Pubitemid 41126030)
28. Goldstein R, Moulds JM, Smith CD, et al. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996;23:1173-9.
29. Galeazzi M, Sebastiani GD, Morozzi G, et al. HLA class II DNA typing in a large series of European patients with systemic lupus erythematosus: correlations with clinical and autoantibody subsets. Medicine (Baltimore) 2002;81:169-78. (Pubitemid 34507204)
30. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-78.
31. Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008;58:359-69. (Pubitemid 351294870)
32. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic in flammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:125-32.
33. Mattey DL, Thomson W, Ollier WE, et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007;56:1408-16. (Pubitemid 46764067)
34. Ikram MA, Seshadri S, Bis JC, et al. Genomewide association studies of stroke. N Engl J Med 2009;360:1718-28.
35. Bjorkbacka H, Lavant EH, Fredrikson GN, et al. Weak associations between human leucocyte antigen genotype and acute myocardial infarction. J Intern Med 2010;268:50-8.
36. Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005;52:3433-8. (Pubitemid 41612209)
37. van Gaalen FA, van Aken J, Huizinga TW, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21. (Pubitemid 38924388)
38. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002;31:355-60. (Pubitemid 34734374)
39. Kaiser R, Barton JL, Chang M, et al. Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. Genes Immun 2009;10:495-502.
40. Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452-6. (Pubitemid 24248251)
41. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009;8:998-1005.
42. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002;33:2396-400.
43. McHugh NJ, Maddison PJ. HLA-DR antigens and anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:1623-4. (Pubitemid 20035087)
44. Asherson RA, Doherty DG, Vergani D, et al. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992;35:124-5.
45. Lewis MJ, D'Cruz D. Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus. Lupus 2005;14(Suppl 1):s17-26. (Pubitemid 40460512)
46. Mikdashi J, Handwerger B, Langenberg P, et al. Baseline disease activity, hyperlipidemia, and hypertension are predictive factors for ischemic stroke and stroke severity in systemic lupus erythematosus. Stroke 2007;38:281-5. (Pubitemid 46184295)
47. Barcellos LF, May SL, Ramsay PP, et al. High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions. PLoS Genet 2009;5:e1000696.
48. Fernando MM, Stevens CR, Sabeti PC, et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet 2007;3:e192.
49. McHugh NJ, Owen P, Cox B, et al. MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis 2006;65:488-94.
50. Jonsen A, Gunnarsson I, Gullstrand B, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 2007;46:1417-21. (Pubitemid 47317086)
51. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.